- Previous close
9.55 - Open
9.66 - Bid 9.02 x 45900
- Ask 9.72 x 46000
- Day's range
9.63 - 9.73 - 52-week range
7.89 - 10.80 - Volume
7,504,642 - Avg. Volume
5,761,310 - Market cap (intra-day)
43.632B - Beta (5Y monthly) 0.24
- PE ratio (TTM)
29.24 - EPS (TTM)
0.33 - Earnings date 31 Oct 2024
- Forward dividend & yield 0.16 (1.63%)
- Ex-dividend date 16 Aug 2024
- 1y target est
10.76
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
www.haleon.com25,408
Full-time employees
31 December
Fiscal year ends
Healthcare
Sector
Drug Manufacturers - Specialty & Generic
Industry
Recent news: HLN
View more
Performance overview: HLN
Trailing total returns as of 22/11/2024, which may include dividends or other distributions. Benchmark is .
YTD return
1-year return
3-year return
5-year return
Compare to: HLN
Select to analyse similar companies using key performance metrics; select up to four stocks.
Statistics: HLN
View moreValuation measures
Market cap
43.28B
Enterprise value
53.75B
Trailing P/E
29.05
Forward P/E
20.83
PEG ratio (5-yr expected)
1.74
Price/sales (ttm)
3.14
Price/book (mrq)
2.09
Enterprise value/revenue
3.80
Enterprise value/EBITDA
19.22
Financial highlights
Profitability and income statement
Profit margin
10.75%
Return on assets (ttm)
--
Return on equity (ttm)
--
Revenue (ttm)
11.24B
Net income avi to common (ttm)
1.21B
Diluted EPS (ttm)
0.33
Balance sheet and cash flow
Total cash (mrq)
531M
Total debt/equity (mrq)
54.18%
Levered free cash flow (ttm)
--